Default Category
-
To Float or Not to Float? (A) (Spanish version)
Alfaro, Laura; Di Tella, Rafael; Vogel, IngridCase HBS-707S08EconomicsOn July 21, 2005 China revalued its decade-long quasi-fixed exchange rate of approximately 8.28 yuan per U.S. dollar by 2.1% to 8.11% and, at the same time, introduced a more market-based exchange rate system. Many analysts and economists were disappointed with what they considered too small a change and called for more flexibility in the U.S. dollar/yuan exchange rate. Modification to China's exchange rate regime had been eagerly anticipated and...Starting at €8.20
-
China: Flotar o no flotar (C) Esquel Group y el Renminbi chino
Alfaro, Laura; Di Tella, Rafael; Vogel, IngridCase HBS-707S10EconomicsEn julio de 2005, China revaluó su moneda en un 2,1% y ajustar su régimen de tipo de cambio hacia un sistema más basado en el mercado. Esquel Group, una gestión familiar, textiles privadas firma especializada en camisas de algodón de alta calidad con su mayoría de base de producción se encuentra en China, estaba entre aquellas empresas que se enfrentan con el reto de hacer frente a la revaluación del yuan y la posibilidad de apreciación futura . ...Starting at €5.74
-
China: Flotar o no Flotar (B) Calendario de cambios relevantes del Renminbi chino
Alfaro, Laura; Di Tella, Rafael; Vogel, Ingrid; Kim, Renee; Russell, WilliamCase HBS-707S11EconomicsEl 21 de julio, 2005, China revaluó su tipo de cambio cuasi-fijo década de duración de aproximadamente 8,28 yuanes por dólar EE.UU. un 2,1% a 8,11% y, al mismo tiempo, introdujo un sistema de tipo de cambio más basado en el mercado. Muchos analistas y economistas se mostraron decepcionados con lo que consideraban un cambio muy pequeño y pidieron una mayor flexibilidad en el tipo de cambio dólar-yuan EE.UU.. Proporciona una línea de tiempo de más ...Starting at €5.74
-
Novozymes: Cracking the Emerging Markets Code
Palepu, Krishna G.; Misztal, KarolCase HBS-112084-EIn 2011, the management of Novozymes, the industrial enzymes leader, reflected on the viability of their positioning in the fast growing, yet increasingly competitive Chinese market. Novozymes, a technological innovation pioneer, was prominent in China's premium enzyme markets, but felt pressure from local low-cost rivals in volume-driven, commoditized segments. How should Novozymes relate to local competitors? By competing on technological innov...Starting at €8.20
-
Investindustrial Exits Ducati
Brochet, Francois; Misztal, KarolCase HBS-113058-EAccounting and ControlIn early 2012, Investindustrial, a European private equity group, publicly announced their intention to sell their 76.7% stake in Ducati Motor Holding S.p.A., an iconic Italian producer of sport performance motorcycles. The decision followed a six-year turnaround during which Ducati returned to profitability and significantly expanded its product line. Investindustrial's team had the following exit alternatives: 1) a trade sale to an automotive b...Starting at €8.20
-
The IASB at a Crossroads: The Future of International Financial Reporting Standards B
Ramanna, Karthik; Misztal, Karol; Beyersdorfer, DanielaCase HBS-113089-EAccounting and ControlSupplement for case 111084. In late 2012, IASB chair Hans Hoogervorst, just over a year into his term, must address several serious geopolitical challenges that can derail IFRS growth. The SEC has issued a report outlining why the U.S. should not adopt IFRS. Other major economies such as Japan and India begin to dither on IFRS as well. The E--the IASB's main backers--is embroiled in a debt crisis that divides it; Britain--the strongest voice for ...Starting at €8.20